The Optical Biopsy Blog - Mauna Kea Technologies' Official Corporate Blog

Sacha Loiseau, Ph.D., President and CEO

Sacha founded Mauna Kea Technologies in May 2000 and has been the CEO ever since. He piloted the development of the Cellvizio product line and brought together a world-class executive team to raise over € 32 million with investors specialized in the health industry. In July 2011, he successfully led the company to an initial public offering on the NYSE Euronext Paris index and raised € 56.5 million to fund a large-scale commercial development. Sacha started his career at the National Center for Space Studies (CNES) in Toulouse and at the Paris Observatory, then joined NASA's Jet Propulsion Laboratory (JPL) in Pasadena, California, as a research scientist. Sacha is a graduate of the École Polytechnique in Paris and has a Ph.D. in Astrophysics and Optical Instrumentation.
Find me on:

Recent Posts

Building Consensus as the International Community of Cellvizio Users Expands

Posted by Sacha Loiseau, Ph.D., President and CEO

June 25, 2014 at 10:44 AM

In any discipline, and particularly in the field of medicine, change takes time. Advanced technology that disrupts the traditional way of doing things requires early adopters who see value and are eager to share the potential with their peers. As technology becomes more accessible, a large community is formed that carries significant weight in advocacy and in practice. That is the case for Cellvizio and the future of Optical Biopsy.

Read More

Topics: Mauna Kea Technologies, Company news, Optical Biopsy

Commitment to Communication: Introducing the Mauna Kea Corporate Blog

Posted by Sacha Loiseau, Ph.D., President and CEO

April 29, 2014 at 11:47 AM

In a world where communication about health, technology, and business is taking place on platforms for real-time conversations with many different audiences, at Mauna Kea Technologies we have decided it’s time to take an important new step in our ongoing commitment to keeping you informed about our progress in delivering the benefits of Cellvizio to patients and clinicians around the world. This new blog is an opportunity for us to provide perspectives on our business strategy and progress.

In the coming months we’ll provide updates on clinical research and publications that support our mission to position optical biopsy as the standard of care in multiple therapeutic areas and indications in the years ahead. We’ll share many of the compelling case studies that show how cutting-edge imaging technology is bringing the smallest microscope in the world to the patient, with critical benefits including real-time evaluation of tissue with immediate diagnostic results to support faster and more effective intervention. We’ll also post content developed by clinicians from around the world who share their perspectives with us, and we’ll give you additional insights about our news to show how important developments fuel our growth.

Read More

Topics: Mauna Kea Technologies, Company news, Optical Biopsy

     

About this blog

The latest news and information about Mauna Kea Technologies and Cellvizio Optical Biopsy, the Fastest Way to See Cancer. 

Subscribe to Email Updates